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1 
INTRODUCTION 1 
Tuberculosis (TB) in children reflects a broad spectrum of disease, ranging from asymptomatic 2 
infection through disseminated disease.
1
 Although a higher proportion of young children develop 3 
disseminated forms of TB (miliary TB and TB meningitis),
2,3
 primary childhood TB is typically more 4 
benign than adult-type TB. The majority (~75%) of disease is intrathoracic,
4 most commonly isolated 5 
mediastinal lymph node, Ghon focus or Ghon complex disease.
5
 In mid-childhood, mediastinal lymph 6 
7 node disease predominates; adult-type disease with pleural effusions and cavitation 
typically emerges during adolescence.
4,6
 The confirmation of TB in children is challenging due 
to the 
8 
paucibacillary nature of the disease, challenges in specimen collection and the wide observed 9 
disease spectrum. In addition to informing clinical care, the use of standard case definitions is 10 
important to enable the adequate comparison of children in clinical research, where the yield of 11 
diagnostic tests, response to treatment, and the efficacy of new drugs or regimen and vaccines are 12 
13 evaluated. National Institute of Health (NIH) International Consensus Case Definitions for 
diagnostic research in childhood TB were proposed in 2012 by an expert panel.
7
 These have not yet 
been 
14 
applied to contact investigations. 15 
The yield of diagnostic tests may correlate with disease spectrum and severity. For example, the 16 
yield of mycobacterial culture is considerably higher in children with extensive intrathoracic 17 
compared to limited disease.
8
  We recently proposed a novel standard approach to describe the 18 
spectrum and severity of TB in children
5
 which considers both the extent (containment) of disease 19 
and the presence of complications; resulting in a final  assignation of “severe” or “nonsevere” 20 
disease, applicable to both intrathoracic and extrathoracic TB.
5
  21 
The  NIH case definition focuses on young children <10 years of age presenting with symptoms of 22 
intrathoracic TB, typically at the hospital or referral level (Table 1), and was thus expected to have 23 
limited applicability to active TB surveillance studies such as household contact tracing. 24 
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2 
Prior to the publication of the NIH definition, we developed standard case definitions for use in a 25 
community-based household contact tracing study. We applied and compare the NIH and the 26 
protocol case definitions and describe the TB disease spectrum and severity  
5
 in our prospective 27 
community-based study . We hypothesized that our protocol case definition would better apply to 28 
our cohort, with anticipated limited disease spectrum and detected through active surveillance. 29 
30 
31 
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3 
STUDY POPULATION AND METHODS 32 
Study design and setting 33 
We analysed data from  a prospective community-based household contact tracing study aimed at 34 
determining the diagnostic utility of 2 commercial Interferon Gamma Release Assays (IGRAs) for 35 
detection of Mycobacterium tuberculosis (M.tb) infection and disease in HIV-infected and uninfected 36 
children. The study was conducted in three impoverished urban communities with high levels of TB 37 
and HIV 
9
 in Cape Town, South Africa, consisting of predominantly South African mixed race and 38 
Xhosa African populations. The adult TB case notification rate in Cape Town was 671 per 100 000 39 
and 315 per 100 000 in children aged 0-14 years in 2012 (Personal communication, Judy Caldwell, 40 
Cape Town City Health Department). 41 
42 
Eligibility and recruitment 43 
HIV-infected and -uninfected children aged 3 months to 15 years with and without documented 44 
M.tb exposure were recruited between December 2007 and June 2012. Focusing on well children, 45 
the study excluded children under 5 kg, with laboratory-documented anemia (Hb < 9g/dL), on 46 
antituberculosis therapy, or where consent was not obtained. Infants below 5 kg were excluded due 47 
to blood volumes. Children on isoniazid preventive therapy (IPT) were not excluded. Enrolment was 48 
deferred if a Mantoux tuberculin skin test (TST) had been placed within 12 weeks, live attenuated 49 
vaccination had been given within 6 weeks, or if there was an acute severe respiratory, diarrheal or 50 
neurologic illness. 51 
52 
A three-pronged approach was employed, recruiting children via either community TB clinics as 53 
household contacts of adult TB cases (who started treatment within preceding 3 months; i.e from 54 
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“TB households”), or from neighbouring households (“community controls”) or from community 55 
paediatric HIV clinics (HIV-infected children with and without documented M.tb exposure). 56 
57 
All symptomatic adult household members were screened for TB and if diagnosed with TB, that 58 
household was reclassified.  Children were investigated at enrolment and follow-up for M.tb 59 
infection and disease, using standard protocols.
10,11
  60 
61 
Study measures 62 
Using methods previously described,
12 the larger study enrolled 1093 children  with median follow-63 
up duration of 15 months.
13 Children were seen at baseline (enrolment), months 3, 6, 15, and in the 64 
case of HIV-infected children, 27 months’ follow-up. From the total enrolled, a dataset was compiled 65 
of all potential TB cases, detected at any (scheduled and unscheduled) study visits. 66 
Children were included in analysis of potential TB cases if they were documented as having 67 
Confirmed, Probable or Possible TB (protocol definition), reported by the study team, parent or 68 
healthcare provider (TB clinic or referral hospital), or if there was laboratory evidence of M.tb, at any 69 
time during the study period. Data sources included the study database, clinic, hospital, and routine 70 
laboratory surveillance data. 71 
Standard methods were used to define TB symptoms,
11
 M.tb contact history, chest radiograph 72 
interpretation
14
 and bacteriology. TB disease spectrum and severity were described;
5
  the most 73 
severe manifestation was reported. 74 
HIV testing was completed on all children with unknown or negative status (Abbott Determine HIV-75 
1/2 rapid test followed by DNA PCR or HIV ELISA depending on whether they were younger or older 76 
than 18 months, respectively, in the case of a positive or indeterminate test). All HIV-infected 77 
children had access to combination anti-retroviral therapy (cART). 78 
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TB exposure history was captured using information including the presence of contact with a known 79 
adult (> 18 years old) household or other TB source case (person currently receiving TB treatment 80 
regardless of sputum smear status or disease type), the level of exposure and the number of TB 81 
cases in the household. The level of exposure was reported as a contact score of 1-10 derived from 82 
combined data assuming that the level of exposure was a product of proximity, duration and 83 
infectivity of exposure.
12
 84 
85 
Measures of TB infection included the TST and IGRAs. The TST (2 TU PPD RT 23, Statens Serum 86 
Institute) was administered intradermally and read using the ballpoint method and callipers at 48-72 87 
hours.  TST was completed at all study visits except at month 6, in the case of a previous reported 88 
TST adverse event, or TST administered within the preceding 3 months. A positive TST was defined 89 
as an induration of ≥10 mm in HIV-uninfected and ≥5 mm in HIV-infected children. The T-SPOT.TB 90 
(Oxford Immunotec, UK)
15
 and the Quantiferon-TB Gold In Tube (QTF-IT, Cellestis, Australia) 
16
 were 91 
completed at all study visits..
17
 IGRA results were reported at the visit closest to the TB episode as 92 
positive (if either QTF or T-SPOT.TB was positive), negative (both tests negative or only 1 available 93 
result, which was negative), indeterminate or not done. M.tb infection was defined as either a 94 
positive TST and/or IGRA. 95 
96 
TB symptoms and signs were classified at the time of the TB episode (Table 1).
7,11,13,18,19
 97 
98 
Bacteriological data included specimen type, number of specimens sent,  number of positive 99 
specimens, result of direct smear microscopy for acid-fast-bacilli (AFB), liquid mycobacterial culture 100 
(mycobacterial growth indicator tubes; MGIT, Becton Dickinson, Sparks, MD, USA),
20-28
 histology, 101 
speciation and drug susceptibility test (DST) pattern using the Genotype® MTBDRplus line probe 102 
assay (Hain Lifescience, Nehren, Germany).
29
 Gastric aspirates were collected in all children younger 103 
than 5 years
13
 and expectorated sputum samples in all older children at baseline and at subsequent 104 
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scheduled or unscheduled study visits where clinically indicated (e.g. new TB symptoms, new 105 
reported TB contact, or previous reported abnormality). 
13
 Samples were collected, transported and 106 
processed following standard guidelines and standard cross-contamination prevention measures 107 
were taken.
30
 PCR identification of M.tb on any culture-positive specimen defined bacteriological 108 
confirmation, while caseating necrosis/granulomas with or without positive microscopy for AFB on 109 
cytology or histology specimens defined histological confirmation. 110 
Radiological data included all available chest radiograph (CXR) reports. Antero-posterior and lateral 111 
CXR were done at all initial visits and at subsequent study visits as clinically indicated. CXRs were 112 
reviewed by two experienced independent blinded reviewers using a standard classification.
14
 113 
Where discrepancies arose, a third blinded, independent reviewer was used. Reviewers reported 114 
CXRs as being “Certain TB,” “Uncertain TB”, “Not TB” or “Normal”. A final radiological classification 115 
was assigned as either “Compatible with TB,” “Abnormal but not compatible with TB” or “Normal”. 116 
In the case of an abnormal CXR deemed not to be compatible with TB, an alternative clinical 117 
diagnosis, where possible, was assigned. 118 
119 
TB disease definitions 120 
The  NIH consensus definition
7
 and  protocol case definition were used (Table 1).  The NIH case 121 
definition classified disease as Confirmed, Probable, Possible, Unlikely or Not TB.
7
 Protocol-specified 122 
case definitions assigned these same case definitions as a function of bacteriological confirmation, 123 
well-defined symptoms/signs, TB-compatible CXR, and TB exposure (Table 1). Tests of infection were 124 
purposefully excluded since they were the index test under evaluation in the study. 125 
126 
TB episodes were classified as “prevalent” (detected within 6 weeks of enrolment) or “incident” (detected 127 
after 6 weeks’ enrolment). 128 
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All protocols were approved by the Health Research Ethics Committee, Stellenbosch University, and 129 
the institutional review boards of Case Western Reserve University, USA, Baylor College of Medicine, 130 
USA and the Charite Institute, Berlin, Germany and local health authorities.  All well children with 131 
M.tb contact or positive TST who were HIV-infected or below 5 years of age were referred for IPT, as 132 
per local and international guidelines.
31,32
 All cases of suspected TB were referred for treatment. 133 
Data management and analysis 134 
Agreement between diagnostic approaches was measured using the Kappa statistic with 95% confidence 135 
intervals (CI). All cases with a potential TB diagnosis in our cohort were included in analysis, regardless of 136 
age.  Odds ratios (OR), calculated with Chi-squared or Fisher’s exact tests, were used to compare disease 137 
severity in HIV-infected vs. uninfected children and in different age and TB exposure groups. The TB disease 138 
spectrum was described. TB incidence rates were calculated by age, HIV and TB exposure status. Data was 139 
analysed using STATA/SE version 12.0 (StataCorp LP, Texas, USA). 140 
141 
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RESULTS 142 
Of 1093 children enrolled, 169 were HIV-infected and 924 were HIV-uninfected; 671 (61%) were 143 
enrolled from TB households, 242 (22%) from neighbouring households, 180 (16%) children from 144 
community HIV clinics, of whom 163 were HIV-infected and 17 were uninfected siblings. Of the 145 
remaining 6 HIV-infected children, 5 were recruited from TB households and 1 from a neighbouring 146 
household. 147 
148 
There were 111 potential TB disease episodes documented in 109 children, of whom 23 (21%) were 149 
HIV-infected. 62 (56%) were prevalent and 49 (44%) incident cases. There was known TB exposure in 150 
82 (74%) episodes. The median M.tb contact score at enrolment in the 109 children was 5 (0-10).  Of 151 
prevalent cases eligible for IPT according to programme criteria, only 5/40 (12.5%) children were on 152 
IPT at the time of TB diagnosis; whilst 5 of 18 (28%) of incident cases had received IPT at diagnosis. A 153 
further 6 (33%) were referred but either failed to attend the clinic or defaulted therapy. 16/22 (72%) 154 
children with a potential TB episode had documented TB exposure but were not referred for IPT 155 
based on programme criteria (HIV-uninfected and older than 5 years of age). Of HIV-infected 156 
children, 83% were on cART at the time of TB diagnosis. 157 
Based on NIH case definitions,
7
 there were 8 episodes of confirmed (Table 3), 12 of probable, 17 of 158 
possible, 3 of unlikely and 2 of not TB disease. Applying protocol-defined case definitions, there were 159 
23 episodes of confirmed (Table 3), 36 of probable, 27 of possible, 0 of unlikely and 21 of not TB. Of 160 
the 111 potential TB disease episodes, 69 were unclassifiable (4 due to insufficient data and 65 due 161 
to lack of symptoms), of whom 18 (26%) had no documented TB exposure, using the NIH definition. 162 
Four TB episodes were unclassifiable using the protocol case definition due to insufficient data; 2 163 
(50%) who had no documented TB exposure. Agreement between the NIH and protocol-defined 164 
approach was 0.30 (95% CI: 0.23; 0.38). 165 
166 
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Using the protocol case definition and excluding the episodes classified as “not TB,” and “unlikely TB,” there 167 
were 62 episodes (72%) of nonsevere and 24 episodes (28%) of severe disease. Of those with severe disease, 168 
all had intrathoracic disease, 2 (6%) had cavities/adult-type disease, 4 (13%) had expansile pneumonia; and 1 169 
(4%) had disseminated disease (miliary TB) [Table 4]. HIV-infected children were more likely to have severe 170 
disease than HIV-uninfected children (OR: 3.87; 95% CI 1.26; 11.81, p=0.0056) Children with a documented 171 
TB source case were less likely to have severe disease than those without known exposure (21% vs. 44%; OR: 172 
0.34, 95%CI: 0.12; 1.01, p=0.025). When stratifying by TB exposure and HIV status, proportions with severe 173 
disease remained unchanged, making it challenging to elucidate whether HIV infection or the lack of 174 
documented TB exposure determined TB disease severity. The proportion of children with severe disease 175 
was similar in children below 2 years of age vs. older children (27% vs. 22%; OR: 0.93, 95%CI: 0.29; 2.71, 176 
p=0.88).9 of the 24 children with severe disease were eligible for IPT based on programme criteria; only 3 of 177 
these had received IPT. Children with known TB exposure at enrolment were more likely to have prevalent 178 
TB (OR: 1.48, 95%CI: 0.55; 3.96, p=0.38) than those without exposure. 179 
180 
TB incidence rates (per 1000 patient years) were 109/1000 and 76/1000 in HIV-infected versus uninfected 181 
children; 106/1000 and 76/1000 in children under versus over two years; 111/1000 and 53/1000 in children 182 
under versus over five years old, and 86/1000 and 74/1000 in those with versus without known M.tb 183 
exposure. 184 
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DISCUSSION 185 
186 This is the first published application of the NIH diagnostic definition for intrathoracic childhood 
TB, published in 2012.
7
 In our community-based diagnostic study, we found that almost two-thirds 
of 
187 
children could not be classified using this definition, despite the presence of severe disease in almost 188 
a third. In contrast, almost all children could be classified using the protocol case definition, which 189 
did not rely on the presence of presenting symptoms. 190 
This is most likely explained by the emphasis in the NIH approach on diagnosing TB in symptomatic 191 
children, not typically seen in contact investigation studies, where the majority of diseased children 192 
are expected to have limited disease and thus more limited symptomatology. The NIH approach 193 
would  thus have limited applicability to paediatric TB studies using active surveillance, e.g. TB 194 
contact investigation, and vaccine trials.
33
 We propose the use of our protocol definition as more 195 
relevant to contact investigation studies. 196 
There was, understandably, poor agreement between the case definitions. Despite the fact that the 197 
protocol case definition did not consider tests of TB infection, almost all children were classifiable 198 
using well quantified M.tb exposure as a proxy for tests of infection.  Well quantified exposure was 199 
200 previously shown to correlate well with tests of infection and suggested as a possible replacement 
for tests of infection in resource-poor settings to guide targeted IPT delivery.
12
 A major difference 201 
resulting from the use of the NIH and protocol case definitions lies in the number of confirmed 202 
cases detected (Table 3). Using the protocol definition, there were almost threefold the number of 203 
204 confirmed cases than with the NIH definition. Only 8 of these 23 cases (with at least bacteriological 
confirmation) had “well-defined symptoms”
18
, although most had symptoms of more acute 205 
duration with or without abnormal CXR. We agree that all 23 children may not have had overt 206 
disease, however, all were treated as TB by the program. Recent well-documented M.tb exposure 207 
with isolated bacteriological confirmation may be described as “acute TB infection” as supported by 208 
natural history studies, where positive mycobacterial cultures were obtained in children with 209 
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normal chest radiographs and a positive TST or history of M.tb exposure.
4
 We appreciate that whilst 210 
the clinical relevance in children with bacteriological confirmation without well-defined TB 211 
symptoms remains unknown and an area of ongoing discussion, it is not imprudent to regard such 212 
cases with high suspicion due to the risk of dissemination in very young or HIV-infected children, 213 
given that laboratory contamination can be excluded. Management should be on a case-by-case 214 
basis until consensus is reached. 215 
The site of TB disease seen in our cohort was almost exclusively intrathoracic, but with a wide 216 
observed disease spectrum and severity, ranging from uncomplicated intrathoracic lymph node 217 
disease to uncontrolled intrathoracic disease with complications (lymph node or other) [Table 4]. 218 
Despite this being a predominantly (62%) asymptomatic (i.e. no “well-defined” symptoms
18
) cohort 219 
of children recruited through active surveillance, 28% of children had severe intrathoracic disease. 220 
HIV-infected children had the highest proportion of severe disease (48%), followed by children 221 
without documented TB source exposure (44%). Possible explanations for the unexpectedly high 222 
rate of severe disease are the high HIV prevalence and the high proportion of young children in our 223 
study (Table 2), both risk factors for severe disease.
2,3,34,35
 HIV infection is associated with a higher 224 
incidence of severe intrathoracic disease including cavities
34
 although not more  disseminated 225 
disease.
34
 HIV-infected children recently started on cART may however be prone to more severe 226 
disease manifestations including TB Immune Reconstitution Inflammatory Syndrome (IRIS).
36
 High TB 227 
incidence rates have been reported in HIV-infected children
37,38
 despite the availability of IPT and 228 
improved immunological function on cART,
39
 consistent with our findings. 229 
Diagnostic and treatment delay in adults
40
 may also have led to delayed presentation of children 230 
resulting in disease progression, especially in children without known TB exposure, where TB may 231 
not have been readily suspected in the absence of a known  source case.
41
 Lastly, poor IPT uptake 232 
may be reflected in the high TB rates seen here in HIV-infected and –uninfected under-five year olds, 233 
despite IPT recommendations. Although IPT would not have prevented the majority of our TB cases, 234 
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12 
which were diagnosed within 6 weeks of enrolment, IPT at the time of source case identification by 235 
the program could have prevented a substantial proportion of disease in child contacts. Active 236 
contact tracing and routine IPT delivery in these communities was documented as limited with no 237 
structured IPT adherence support offered by the TB program.
42,43
 We have subsequently supported 238 
the implementation of structured IPT delivery tools to improve uptake and adherence.
44
 239 
240 
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CONCLUSIONS 241 
The current NIH case definition for paediatric intrathoracic TB has limited applicability to household 242 
contact studies where, as shown in  this study from a high-TB burden setting, a surprisingly wide 243 
spectrum of TB disease was observed in HIV-infected and uninfected children. Further work is 244 
needed to develop paediatric TB case definitions to ensure that the wide spectrum of relevant 245 
paediatric TB observed in clinical research is captured, including in contact investigation studies. 246 
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Table 1. Definition and comparison between NIH and protocol case definitions for pediatric 
tuberculosis 
Disease 
categories 
NIH Case definition
7
Protocol Case definition Key differences 
Confirmed TB ≥1 symptom/sign
7
 together
with microbiological 
confirmation of 
Mycobacterium tuberculosis 
(M.tb)  
Bacteriological or histological
1 
confirmation of M.tb, either 
1.alone,
2
 (with/without  TB
exposure/ alternative (non-TB) 
CXR diagnosis), or with  
2. either a TB-compatible CXR,
or 
3. well-defined
symptoms/signs
3,4
Bacteriological 
confirmation alone 
considered and symptoms 
not mandatory in protocol 
case definition. 
Additional symptoms and 
signs considered in the 
protocol case definition. 
Probable TB ≥1 symptom/sign and a TB-
compatible CXR and: 
1.either a positive
treatment response, or 
2.documented exposure to
M.tb, or 
3. immunological evidence
of M.tb infection 
1. Nonspecific histology
5
 with
1.1. a TB-compatible CXR, or 
1.2. symptoms/signs, or 
2. A TB-compatible CXR with
2.1. symptoms/signs, or 
2.2. TB exposure 
Symptoms/signs not 
mandatory in protocol 
definition; tests of 
infection and treatment 
response not considered in 
protocol case definition. 
Additional symptoms and 
signs considered in the 
protocol case definition. 
Possible TB ≥1 symptom/sign and either 
1.a positive treatment
response or documented 
exposure to M.tb or 
immunological evidence of 
Either of the following: 
1. nonspecific histology, or
2. a TB-compatible CXR, or
3. symptoms/signs
with or without TB exposure 
Symptoms/signs not 
mandatory in protocol 
definition; TB-compatible 
CXR alone is defined as 
possible TB in protocol 
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M.tb infection, or: 
2. A TB-compatible CXR
case definition; tests of 
infection and treatment 
response not considered in 
protocol case definition. 
Additional symptoms and 
signs considered in the 
protocol case definition. 
Unlikely TB ≥1 symptom/sign but not 
fitting any of above 
definitions, but with no 
alternative established 
diagnosis 
Abnormal, TB-incompatible CXR 
with no alternative radiological 
or clinical diagnosis, with or 
without  TB exposure 
Symptoms/signs not 
mandatory in protocol 
case definition, otherwise 
similar. 
Additional symptoms and 
signs considered in the 
protocol case definition. 
Not TB ≥1 symptom/sign, not fitting 
any of the above 
definitions, and with an 
established alternative 
diagnosis 
Abnormal,TB-incompatible CXR 
with an alternative radiological 
or clinical diagnosis, with or 
without  TB exposure 
Symptoms/signs not 
mandatory in protocol 
definition, otherwise 
similar 
1
Histological confirmation implies Ziel Nielsen Stain (Zn) positive with granulomatous inflammation and/or caseating 
necrosis 
2
Area of ongoing clinical debate/discussion 
3
 Symptoms/signs include any or more than one of the following  
Cough: persistent, non-remitting cough for more than 2 weeks, not responding to a course of antibiotics 
Weight loss/ failure to thrive: unexplained weight loss of >5% vs. the highest recorded weight /clear deviation from 
previous growth trajectory ±documented crossing of centile lines in preceding 3 months± weight for age z-score of ≤-2 with 
no previous/recent growth trajectory information, not responding to nutritional rehabilitation/cART  
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Persistent unexplained fever: subjectively reported by guardian and a temperature of >38 degrees Celsius for more than 
one week objectively recorded at least once.  
Persistent, unexplained reduced playfulness or activity: perceived and reported by the parent or caregiver.   
4
Protocol defined symptoms and signs are any of the above as well as or any of the following, in isolation:  
Neck nodes/visible neck swelling: defined as noticed by the parent/caregiver in the preceding month   
Night sweats: reported by caregiver of a drenching nature, requiring a change of clothing.  
Convulsions, lethargy or a decreased level of consciousness: defined as reported by the caregiver in the preceding two 
weeks  
5 Zn- with granulomatous inflammation and/or caseating necrosis 
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Table 2.  Characteristics of children enrolled in a community-based diagnostic study (N=1093 
children) at enrolment and at the time of diagnosis of a potential disease episode (N=109) 
Characteristics Total cohort (N =1093) Children with potential TB (N=109) 
Age at enrolment (months: 
median, range) 
61 (3-190) 39 (5-184) 
Age at TB episode N/A 41 (5-188) 
Under 2 years of age [N (%)] 197 (18) 26 (23) 
Under 5 years age [N (%)] 534 (49) 74 (67) 
HIV-infected [N (%)] 169 (15) 23 (21) 
Median CD4 count at enrolment: 
Absolute (range), % (range) 
1400 (35-4200), 28.5 (3-47) 1450 (35-3700), 27 (3-44) 
Median CD4 count at TB episode: 
Absolute (range), % (range) 
N/A 1232 (35-2601), 27 (3-47) 
Follow-up - HIV-infected children 
(months: median, range) 
15 (0-29) 15 (3-28) 
Follow-up  HIV-uninfected children 
(months: median, range) 
15 (0-21) 15 (0-21) 
Ethnicity: Mixed race [N (%)] 717 (66) 73 (67) 
Ethnicity: Xhosa [N (%)] 365 (33) 35 (32) 
Ethnicity: Other [N (%)]  11 (1)  1 (1) 
Community A [N (%)] 355 (32) 28 (26) 
Community B [N (%)] 359 (33) 45 (41) 
Community C [N (%)] 379 (35) 36 (33) 
Recruited from TB household [N 671 (61) 76 (70) 
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(%)] 
Recruited from neighbouring 
household [N (%)] 
242 (22) 13 (12) 
Recruited from community HIV 
clinic [N (%)] 
180 (16) 20 (18) 
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Table 3. Comparison of diagnostic features in children with confirmed tuberculosis as classified 
by the NIH and protocol case definitions 
Confirmed TB based on the NIH definition (N=8) N (%) 
Bacteriological confirmation and symptoms 2 (25.0) 
Bacteriological confirmation, symptoms and a lobar pneumonia on CXR 1 (12.5) 
Bacteriological confirmation, symptoms and documented TB exposure 3 (37.5) 
Bacteriological confirmation, symptoms, TB exposure together with interstitial 
pneumonia on CXR 
1 (12.5) 
Bacteriological confirmation, symptoms, TB exposure and a TB-compatible CXR 1 (12.5) 
Confirmed TB based on the protocol definition (N=23) N (%) 
Bacteriological confirmation alone 1 (4) 
Bacteriological confirmation (MDR M.tb) with multiple palpable cervical lymph 
nodes (1.5 cm diameter)
1 (4) 
Bacteriological confirmation with  interstitial pneumonia on CXR 1 (4) 
Bacteriological confirmation with, lobar pneumonia and acute respiratory 
symptoms 
1 (4) 
Bacteriological confirmation and TB exposure
 
(“acute infection”) 6 (26) 
Bacteriological confirmation, TB exposure and an interstitial pneumonia on CXR 1 (4) 
Bacteriological confirmation, TB exposure, lobar pneumonia on CXR  and acute 
respiratory symptoms
1 (4) 
Bacteriological confirmation, TB exposure and a TB-compatible CXR 3 (13) 
Bacteriological confirmation and well-defined symptoms 2 (9) 
Bacteriological confirmation, well-defined symptoms and interstitial pneumonia 
on CXR 
1 (4) 
Bacteriological confirmation, well-defined symptoms and documented TB 3 (13) 
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exposure
Bacteriological confirmation, well-defined symptoms, documented TB exposure 
and interstitial pneumonia on  CXR 
1 (4) 
Bacteriological confirmation, well-defined symptoms, documented TB exposure 
and a TB-compatible CXR
1 (4) 
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Table 4. Tuberculosis disease spectrum observed in children with confirmed, probable and 
possible tuberculosis based on the protocol case definition (N=86) 
N (% of N=86) 
Intrathoracic tuberculosis 
-Isolated uncomplicated intrathoracic lymph node disease 28 (32) 
-Controlled, uncomplicated intrathoracic (parenchymal) disease (n=29) and 3 with 
additional uncomplicated intrathoracic lymph node disease 
32 (37) 
-Pleural effusion with uncomplicated intrathoracic lymph node disease  1 (1) 
-Complicated intrathoracic lymph node disease (8 in isolation);  2 had additional 
controlled uncomplicated intrathoracic (parenchymal) disease 
10 (12) 
-Uncontrolled uncomplicated intrathoracic (parenchymal) disease, of which 2 had 
additional uncomplicated intrathoracic lymph node disease 
 7 (8) 
-Disseminated disease (miliary TB) with bilateral small pleural effusions and 
uncomplicated intrathoracic lymph node disease 
 1 (1) 
-Uncontrolled complicated intrathoracic disease (complications were mostly 
lymph node related) 
 7 (8) 
Extrathoracic tuberculosis 
-Controlled uncomplicated cervical adenitis  1 (1) 
Note: Entities listed show where there was overlap between more than one disease entity. Disease extent (controlled vs. 
uncontrolled) and the presence of complications are described using a standard approach used to describe disease 
spectrum and severity.
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